Study #2023-0647
A phase 1, open-label, multicenter study of INCA033989 in participants with Myeloproliferative Neoplasms.
MD Anderson Study Status
Enrolling
Treatment Agent
INCA033989
Description
This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered in participants with myeloproliferative neoplasms.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloproliferative Neoplasms
Study phase:
Phase I
Physician name:
Lucia Masarova
Department:
Leukemia
For general questions about clinical trials:
1-888-356-1897
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.